BetterLife Pharma Inc. BETRF
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 114.01% | 22.45% | -35.38% | -47.49% | -39.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 126.13% | 23.64% | -29.15% | -46.39% | -54.10% |
| Operating Income | -126.13% | -23.64% | 29.15% | 46.39% | 54.10% |
| Income Before Tax | -308.34% | -206.73% | 49.02% | -164.32% | 65.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -308.34% | -206.73% | 49.02% | -164.32% | 65.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -30.00% | 180.65% | -96.38% | 126.58% | 9.38% |
| Net Income | -314.92% | -198.66% | 47.00% | -166.91% | 65.76% |
| EBIT | -126.13% | -23.64% | 29.15% | 46.39% | 54.10% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -283.33% | -163.64% | 55.00% | -155.88% | 72.41% |
| Normalized Basic EPS | -280.00% | -58.33% | 65.71% | -1,300.00% | 72.22% |
| EPS Diluted | -287.50% | -107.14% | 69.49% | -164.71% | 72.73% |
| Normalized Diluted EPS | -280.00% | -58.33% | 65.71% | -1,300.00% | 72.22% |
| Average Basic Shares Outstanding | 8.43% | 18.70% | 16.95% | 17.30% | 24.29% |
| Average Diluted Shares Outstanding | 8.43% | 18.70% | 16.95% | 3.48% | 24.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |